Brexit Implications on the Life Sciences Sector
|
|
- Emory Sparks
- 5 years ago
- Views:
Transcription
1 Brexit Implications on the Life Sciences Sector Holger Stratmann Attorney at Law, Partner 1 Life Science IP Seminar 2017
2 Separating Facts From Fiction Impact On Existing IP The Unknown Future What To Do Now 2 Life Science IP Seminar 2017
3 3 Life Science IP Seminar 2017
4 4 Life Science IP Seminar 2017
5 FACTS US$25b in revenue generated by European biotechs in 2015 Almost US$10b in capital raised by European biotechs in ,259 biotech companies in Europe with over 72,000 employees 1,045 biotech companies in UK pharmaceutical market value in Europe approx. US$280b more than 700,000 people are employed in the European pharmaceutical industry UK is one of the largest recipients of research funding in the EU UK is European HQ location of choice for over a dozen global pharma/biotech companies 5 Life Science IP Seminar 2017
6 FACTS and have given reassurance that they will remain committed to the UK is in the midst of a huge 330 million project developing a new R&D hub and headquarters in Cambridge announced a 275 million investment in various UK sites to boost production and support delivery of its latest respiratory and large molecule biologic medicines 6 Life Science IP Seminar 2017
7 FACTS 7 Life Science IP Seminar 2017
8 8 Life Science IP Seminar 2017
9 9 Life Science IP Seminar 2017
10 IMPACT OF THE BREXIT ON EU TRADEMARKS EU Trademark regime is only available to EU Member States Existing EU Trademark registrations will continue to apply in the other EU Member States cease to apply in the UK likely that transitional provisions would be put in place to allow brand owners to convert part of their Union Trademarks to national UK registrations (possibly retaining their original priority dates) NEW EU Trademark registrations will NOT cover the UK 10 Life Science IP Seminar 2017
11 IMPACT OF THE BREXIT ON EU TRADEMARKS EU Trademark will lose its effect in the UK convert UK-part into national UK trademarks NEW filings will NOT cover the UK 11 Life Science IP Seminar 2017
12 12 Life Science IP Seminar 2017
13 IMPACT OF THE BREXIT ON DESIGNS RCD regime is only available to EU Member States Existing RCDs will continue to apply in the other EU Member States cease to apply in the UK likely that transitional provisions would be put in place to allow design owners to convert part of their RCD to national UK registrations (possibly retaining their original priority dates) NEW RCDs will NOT cover the UK 13 Life Science IP Seminar 2017
14 IMPACT OF THE BREXIT ON DESIGNS RCD will lose its effect in the UK convert UK-part into national UK designs NEW filings will NOT cover the UK 14 Life Science IP Seminar 2017
15 15 Life Science IP Seminar 2017
16 IMPACT OF THE BREXIT ON EUROPEAN PATENTS (EPC) European Patent Convention: Multilateral treaty instituting the European Patent Organisation and providing an autonomous legal system according to which European patents are granted EU membership is NOT required for being part of the EPO system No substantial changes expected 16 Life Science IP Seminar 2017
17 IMPACT OF THE BREXIT ON EUROPEAN PATENTS (EPC) EPC Member States EU Member States 17 Life Science IP Seminar 2017
18 IMPACT OF THE BREXIT ON NATIONAL (UK) PATENT APPLICATIONS UK Applications currently, interpretation of the Biotech Directive (98/44/EC) by the CJEU is binding on the UK UKIPO brought its practice into line with CJEU rulings C -34/10 ( Brüstle ) and C-364/13 ( International Stem Cell Corporation ) on the patentability of human embryonic stem cells post-brexit, it will be the UK courts, rather than the CJEU, who will rule on such matters and therefore there could be divergence in UK and EU law 18 Life Science IP Seminar 2017
19 19 Life Science IP Seminar 2017
20 IMPACT OF THE BREXIT ON SPC s SPCs are national rights granted by UKIPO SPCs can only be enforced in the UK EU laws will be converted into UK law subject to amendment, repeal or improvement by parliament likely that UK will retain the system for the maintenance and grant of SPCs (necessary) amendments may no longer be appropriate the use the date that a product is first authorized in the European Economic Area (EEA) to calculate the duration of an SPC may no longer be appropriate to require that a product be authorized in all EU Member States in order for the award of a six-month extension of the SPC term to apply 20 Life Science IP Seminar 2017
21 IMPACT OF THE BREXIT ON SPC s Pharmaceutical Products: Regulations (EC) No. 469/2009 (EC) No. 1901/2006 Plant Protection Regulation (EC) No. 1610/96 21 Life Science IP Seminar 2017
22 22 Life Science IP Seminar 2017
23 IMPACT OF THE BREXIT ON TRADE SECRETS EU Trade Secrets Directive (2016/943) has come into force on July 5, 2016, setting minimum level of protection EU Member States have 2 years to implement it into national law UK may not implement, but already has strong trade secret protection 23 Life Science IP Seminar 2017
24 The Unknown Future 24 Life Science IP Seminar 2017
25 25 Life Science IP Seminar 2017
26 THE NORWEGIAN MODEL Leave the EU, but remain a member of the European Economic Area (EEA) 26 Life Science IP Seminar 2017
27 THE NORWEGIAN MODEL Situation UK remains part of EEA and keeps the 4 freedoms of people, capital, goods and services Potential Implications UK would need to contribute to the EU budget and comply with EU social, employment and production regulation Impact on Life Science Companies would allow the UK to retain access to the EU market and participate in trials EU authorized medical products would have to be nationally authorized in the UK alternatively the UK may wish to enact legislation which gives automatic effect to EU marketing authorisation decisions. 27 Life Science IP Seminar 2017
28 THE SWISS MODEL Leave the EU, re-join the European Free Trade Association (EFTA), but stay outside the EEA 28 Life Science IP Seminar 2017
29 THE SWISS MODEL Situation UK enters into a bilateral integration treaty with the EU Potential Implications UK would have access to some areas of the Single Market, at the cost of adopting the relevant EU regulations Impact on Life Science Companies UK would need to approve medicines and grant clinical trial authorizations etc., separately from the EU (and the EEA) UK would recognize the quality of pharmaceuticals manufactured in the EU and vice versa, thus ensuring quicker market access 29 Life Science IP Seminar 2017
30 THE TURKISH MODEL Leave the EU, but join an EU customs union 30 Life Science IP Seminar 2017
31 THE TURKISH MODEL Situation giving only partial access to the EU single market Potential Implications it is not an economically favourable option Impact on Life Science Companies no positive impact 31 Life Science IP Seminar 2017
32 THE CANADIAN MODEL Leave the EU, but negotiate individual trade terms to retain at least some access to the single market 32 Life Science IP Seminar 2017
33 THE CANADIAN MODEL Situation UK negotiates a Free Trade Agreement (FTA) with the EU Potential Implications tariff-free trade between the UK and the EU gives access to the single market for goods without all of the obligations that come with the Swiss and Norway models, such as contributing to the EU budget or signing up to free movement Impact on Life Science Companies depending on what agreement is reached UK may want to negotiate as complete market access as possible depending on the concessions demanded by the EU, extensive market access may be feasible or not 33 Life Science IP Seminar 2017
34 THE UK MODEL?? Leave the EU, and fall back on World Trade Organization (WTO) trade terms 34 Life Science IP Seminar 2017
35 THE UK MODEL Situation UK does not establish any new trade agreements with the EU Potential Implications only WTO terms apply UK goods and services would be treated in the same ways as those of third countries like Hong Kong or Singapure Impact on Life Science Companies scenario presumes a complete separation of the UK system for pharmaceutical regulation from that of the EU under a Most Favoured Nation (MFN) status, a 0% tariff would apply to the UK on pharmaceuticals there could be tariff implications component parts and broader goods used there could be scope to agree mutual recognition of GMP inspections, subject to negotiations and the willingness of the EU 35 Life Science IP Seminar 2017
36 36 Life Science IP Seminar 2017
37 PARALLEL IMPORTATION Parallel Importation is a Big Issue for Pharmaceutical Companies pricing and reimbursement of medicines are not harmonized and falls under the exclusive competence of EU Member States third parties are free to buy up branded medicines in an EU Member State where the price is typically low, and gain significant profit by selling in a more expensive EU Member State, by undercutting pharmaceutical companies prices EU Operates a Principle of Exhaustion of Rights IP rights holders cannot use their IP rights to prevent free movement of goods within the EEA in circumstances where a product has been placed on the market by the IP right holder or with his consent 37 Life Science IP Seminar 2017
38 PARALLEL IMPORTATION Current Situation UK recognizes the doctrine of regional exhaustion of rights within the European Economic Area (EEA) goods which are initially placed for sale in one Member State of the EEA may then be transported to the UK for sale without infringing UK trademark or patent rights Post-Brexit UK will leave the EU however, it is not presently clear whether UK will also exit the EEA 38 Life Science IP Seminar 2017
39 PARALLEL IMPORTATION If the UK Remains Part of the EEA EU exhaustion of rights continues to apply free movement of goods will be preserved If UK Leaves EEA EU exhaustion of rights rules will cease pharmaceutical companies may be able to assert their IP rights to stop parallel importation into the UK however, UK could legislate so that the position remains the same (as is currently), with the relevant territory being the EEA and the UK 39 Life Science IP Seminar 2017
40 40 Life Science IP Seminar 2017
41 MARKETING AUTHORIZATION Medicinal products must obtain a marketing authorization (MA) from an appropriate regulatory body before they can be sold in the UK Currently three routes for getting marketing authorization in the UK: Centralized Procedure (Directive 2001/83/EC) making one application to the European Medicines Agency (EMA) (a single marketing authorization is obtained) Decentralized Procedure (Directive 2001/83/EC) making multiple applications to each individual EU member state where marketing authorization is sought (separate national authorizations are obtained); 41 Life Science IP Seminar 2017
42 MARKETING AUTHORIZATION Mutual Recognition Procedure a medicine is authorized in one EU member state and a later application is made for this authorization to be recognized in other member states (separate national authorizations are obtained) 42 Life Science IP Seminar 2017
43 MARKETING AUTHORIZATION Post-Brexit (new authorizations) Remain Part of the System UK could remain part of the system like Norway MAs issued by EMA will continue to be automatically valid in the UK UK would have no formal legislative or administrative role Operate Own National Authorization System Medicines & Health Products Regulatory Agency (MHRA) will inherit work from EMA MHRA will have to recruit and train additional staff; longer proceedings necessity to make separate applications for marketing authorizations in the EU and the UK 43 Life Science IP Seminar 2017
44 MARKETING AUTHORIZATION Post-Brexit (granted authorizations) marketing authorizations granted by the UK will be unaffected marketing authorizations granted in the EU under the centralized procedure prior to the exit will be recognized by the UK centralized marketing authorizations covering the EU held by UK companies will have to be transferred to companies established in EU countries unless mutual recognition agreements are put in place 44 Life Science IP Seminar 2017
45 45 Life Science IP Seminar 2017
46 CLINICAL TRIALS Currently UK is the EU s most popular location for phase I trials UK ranks second, after Germany, for phase II trials UK is third, behind Germany and Spain, for phase III studies Post-Brexit pharmaceutical companies and medical technology suppliers may favor running trials in EU member states, as it will give them access to a larger market 46 Life Science IP Seminar 2017
47 CLINICAL TRIALS If the UK Remains Part of the EEA UK may continue to retain some benefits as the centralized marketing authorization procedure will continue to apply in return, drugs that have been approved in the UK will be approved across Europe as well If UK Leaves EEA there may be additional controls that would have to be negotiated, which could slow regulatory approvals 47 Life Science IP Seminar 2017
48 CLINICAL TRIALS 2018: EU Clinical Trials Regulation (EU No 536/2014) aiming to facilitate pan-european clinical trials will allow for central application and approval to conduct trials across the EU (a much larger and potentially more lucrative market of some 500 million potential patients compared with the UK s 60 million or so ) UK involvement in these trials will become more difficult and costly pharmaceutical companies may need to set up separate trials for the UK, leading to higher costs and more time consuming processes companies will not wish to incur the cost of trials in the UK when they already have won EU-wide approval however, mutual recognition arrangements may be arranged to minimize any such inefficiencies brought about by Brexit 48 Life Science IP Seminar 2017
49 49 Life Science IP Seminar 2017
50 EMPLOYEES Currently UK based pharmaceutical industry directly employs around 73,000 people, of which 10,000 work in R&D multinational pharma companies with their base in the UK typically employ international teams the pharmaceutical and life sciences industries in the UK employ approximately 5,000 non-british EU citizens 50 Life Science IP Seminar 2017
51 EMPLOYEES Post-Brexit should the UK change its migration policy and restrict freedom of labor as part of its exit deal with the EU, this may impact both established companies and the core research base in the UK companies may consider relocating to other EU countries as this would facilitate the employment of EU nationals relocating to the EU could mean that UK employees would then face burdensome visa processes and costs as working for an UK based company might become less attractive for highly educated foreign employees, these employees may turn to companies in the EU 51 Life Science IP Seminar 2017
52 EMPLOYEES If the UK Remains Part of the EEA people will still be able to move freely across borders If UK Leaves EEA free movement of workers between the UK and the other EU member states would come to an end impact on the movement of scientists, life sciences companies staff and researchers across Europe it also poses questions regarding the status of EU citizens currently employed in the UK in the life sciences sector 52 Life Science IP Seminar 2017
53 53 Life Science IP Seminar 2017
54 WHAT TO DO NOW? analyze the impact of separate approvals processes and labelling for the UK develop assessment criteria that can be used on a case -by-case basis if a separate UK approvals process is required, to make cost -efficient launch decisions analyze the impact of WTO tariffs on trade profitability and R&D efficiency, and conduct locational analysis to check if changes to supply chain would lead to savings (and be ready to implement at point of exit) 54 Life Science IP Seminar 2017
55 WHAT TO DO NOW? model the impact of the loss of the free movement of people gather information on the organizations national status of current UK and EU workforce and talent pool understand which existing EU R&D funding will be impacted and the possible consequences strengthen existing relationships and identify new potential collaborators 55 Life Science IP Seminar 2017
56 Thank you for your attention Holger Stratmann Attorney at Law Partner 56 Life Science IP Seminar 2017
IP IN A POST-BREXIT EUROPE ENSURING YOUR EUROPEAN IP RIGHTS ARE PROTECTED DATE: 10 NOVEMBER 2016 PRESENTERS: CHRIS FINN, BEN GRAU AND GRAHAM MURNANE
IP IN A POST-BREXIT EUROPE ENSURING YOUR EUROPEAN IP RIGHTS ARE PROTECTED DATE: 10 NOVEMBER 2016 PRESENTERS: CHRIS FINN, BEN GRAU AND GRAHAM MURNANE BACKGROUND A fundamental aspect of the European Union
More informationEffect of Brexit on IP protection
Effect of Brexit on IP protection Contents Introduction 1 Patents 2 UK Patents 6 International Patent Applications 7 Unitary Patent and Unified Patent Court 8 Supplementary Protection Certificates 10 Plant
More informationCall for evidence: EEA workers in the UK labour market
Migration Advisory Committee 2 nd Floor Peel Building 2 Marsham Street London SW1P 4 DF 24 October 2017 Dear Colleague Call for evidence: EEA workers in the UK labour market The Royal Pharmaceutical Society
More informationInformation note on the UK referendum decision and its potential implications
Information note on the UK referendum decision and its potential implications The AIRE Centre is a specialist legal charity. We use the power of European law to protect your human rights. On the 23rd June
More informationPatent reform package - Frequently Asked Questions
EUROPEAN COMMISSION MEMO Brussels, 11 December 2012 Patent reform package - Frequently Asked Questions I. Presentation of the unitary patent package 1. What is the 'unitary patent package'? The 'unitary
More informationBREXIT. Employment law consequences of Brexit
BREXIT Employment law consequences of Brexit INTRODUCTION 1. On 23 June 2016, the United Kingdom (UK) voted to leave the European Union (EU). The precise timing of the formal exit process remains unclear.
More informationHerbert Smith Freehills Insights membership, each of which provide to a greater or
COMPETITION REGULATION & TRADE BRIEFING FUTURE UK TRADE RELATIONS WITH THE EU AND WITH THIRD COUNTRIES AUGUST 2016 London As an EU member state the UK is currently part of the EU internal market, which
More informationBrexit essentials: Alternatives to EU membership
Brexit essentials: Alternatives to EU membership This is the second in a series of briefings covering the essential aspects of the UK s referendum on EU membership, which Prime Minister David Cameron has
More informationBrexit Seminar : Emergent Understandings of Consequences and Impacts: The Potential Impact of Brexit on Scotland and UK
Brexit Seminar : Emergent Understandings of Consequences and Impacts: The Potential Impact of Brexit on Scotland and UK @UofGVC @UofGlasgow Professor Sir Anton Muscatelli Principal, University of Glasgow
More information5 TAKEAWAYS ON BREXIT: Outlining Possible Scenarios for a New UK-EU Relationship and their Impact on Citizens POLICY DIGEST
5 TAKEAWAYS ON BREXIT: Outlining Possible Scenarios for a New UK-EU Relationship and their Impact on Citizens POLICY DIGEST TABLE OF CONTENTS Introduction... 3 Partnership and objectives... 3 Structure
More informationA Brexit analysis for client-facing teams 26 March 2018
The draft agreement on UK withdrawal A Brexit analysis for client-facing teams 26 March 2018 Overview: Draft Withdrawal Agreement The UK and EU have published an updated Draft Withdrawal Agreement which
More informationDHS Patentanwaltsgesellschaft mbh Munich. RECENT RULINGS OF THE EUROPEAN COURT OF JUSTICE ON SPCs
Dr. Stefan Danner December 2011 German and European Patent Attorney danner@dhs-patent.de RECENT RULINGS OF THE EUROPEAN COURT OF JUSTICE ON SPCs In the last few months, the European Court of Justice (ECJ)
More informationEU Notice To Stakeholders Is Accurate, But Misleading
Portfolio Media. Inc. 111 West 19 th Street, 5th Floor New York, NY 10011 www.law360.com Phone: +1 646 783 7100 Fax: +1 646 783 7161 customerservice@law360.com EU Notice To Stakeholders Is Accurate, But
More informationUnitary patent and Unified Patent Court: the proposed framework
Unitary patent and Unified Patent Court: the proposed framework The adoption of two key regulations late last year have paved the way for the long-awaited unitary patent and Unified Patent Court By Rainer
More informationFree-from thresholds, may contain what happens at the moment of Brexit?
Free-from thresholds, may contain what happens at the moment of Brexit? 21 November 2017 Brian Kelly bkelly@cov.com Overview of Covington In an increasingly regulated world, we have an exceptional ability
More informationIP Litigation in Life Sciences Germany 2016
IP Litigation in Life Sciences Germany 2016 Dr. Jan B. Krauss, Patent Attorney, Munich 2016 WIPO Conference Life Sciences Dispute Resolution Agenda The current landscape of life sciences enforcement in
More informationIP in a World of Change: Europe and Brexit; United States and its exit from the TPP: Where does IP Protection come in?
IP in a World of Change: Europe and Brexit; United States and its exit from the TPP: Where does IP Protection come in? Europe and Brexit - Exhaustion and litigation issues Ari Laakkonen, Powell Gilbert
More informationPROPOSALS FOR CREATING UNITARY PATENT PROTECTION IN THE EUROPEAN UNION
PROPOSALS FOR CREATING UNITARY PATENT PROTECTION IN THE EUROPEAN UNION The idea of a Community Patent, a single patent that can be enforced throughout the European Union (EU), is hardly new. The original
More informationIBC s 20 th Conference on. Paediatric Extensions Issues and Challenges. Christopher Stothers 22 February 2012
IBC s 20 th Conference on Biotech & Pharmaceutical Patenting 2012 Paediatric Extensions Issues and Challenges Christopher Stothers 22 February 2012 1 Overview of this Session Problem/Solution Opportunity/Threats
More informationDenmark and Italy Trade-related intellectual property rights, access to medicines and human rights
Summary Denmark and Italy Trade-related intellectual property rights, access to medicines and human rights October 2004 1. Denmark and Italy, as members of the European Union (EU), have committed themselves
More informationBrexit Paper 20: The Impact of No Deal
1 Brexit Paper 20: The Impact of No Deal This paper was originally commissioned by the House of Commons Foreign Affairs Select Committee and published in March 2017 Executive Summary A no-deal would bring
More informationEricsson Position on Questionnaire on the Future Patent System in Europe
Ericsson Position on Questionnaire on the Future Patent System in Europe Executive Summary Ericsson welcomes the efforts of the European Commission to survey the patent systems in Europe in order to see
More informationYoung EPLAW Congress. Bolar provision: a European tour. Brussels, 27 April 2015 Guillaume Bensussan Kathy Osgerby Agathe Michel de Cazotte
Young EPLAW Congress Bolar provision: a European tour Brussels, 27 April 2015 Guillaume Bensussan Kathy Osgerby Agathe Michel de Cazotte Introduction Bolar provision: a European tour Part 1 UK A) Recent
More informationDr Julian M. Potter February 2014
The European Patent Court and Unitary Patent Don t Panic Be Prepared Dr Julian M. Potter February 2014 (c) Dr Julian M Potter 2014 1 Patent in Europe - now National patents through respective national
More informationThe Unitary Patent Plan Beta Update on National Case Law in Europe
The Unitary Patent Plan Beta Update on National Case Law in Europe Leythem Wall 28 November 2013 Declarations of Non-Infringement Article 15 of the Unified Patent Court (UPC) Agreement sets out the areas
More informationForeign Patent Law. Why file foreign? Why NOT file foreign? Richard J. Melker
Foreign Patent Law Richard J. Melker Why file foreign? Medical device companies seek worldwide protection (US ~50% of market) Patents are only enforceable in the issued country Must have patent protection
More informationHow can businesses in the EU prepare for Brexit: Deal or no Deal? 6 December 2018
How can businesses in the EU prepare for Brexit: Deal or no Deal? 6 December 2018 WITH YOU TODAY Insert picture CHRISTINE SULLIVAN Attorney and Director Brussels 2 Where are we now? The EU and the UK reached
More informationNick Fahy and Tamara Hervey, 22 November 2018
1 Briefing note for House of Commons Health Committee on the Draft Agreement on the withdrawal of the United Kingdom of Great Britain and Northern Ireland from the European Union and the European Atomic
More informationEuropean Commission Questionnaire on the Patent System in Europe
European Commission Questionnaire on the Patent System in Europe Response by: Eli Lilly and Company Contact: Mr I J Hiscock Director - European Patent Operations Eli Lilly and Company Limited Lilly Research
More informationInternational Employee Mobility after Brexit
International Employee Mobility after Brexit September 2016 Brussels / Dusseldorf / Hamburg / London / Manchester / Milan / Munich / Paris / Rome / Shanghai / Silicon Valley International Employee Mobility
More informationLIST OF KEY MARKET ACCESS BARRIERS IN MEXICO UNDER THE MARKET ACCESS STRATEGY 22 September 2016 MAAC/
Barrier LIST OF KEY MARKET ACCESS BARRIERS IN MEXICO UNDER THE MARKET ACCESS STRATEGY 22 September 2016 MAAC/2016-037 Description Protection and enforcement of Intellectual Property Rights The huge market
More informationThe Impact of Brexit on Employment Law
1 The Impact of Brexit on Employment Law Summary The UK has played a central role in bringing about law reform at an EU level in the area of equality and employment rights. Currently, principles of CJEU
More informationBriefing: The EU referendum and housing associations
8 April 2016 Briefing: The EU referendum and housing associations Framing the debate, and posing the questions Summary of key points: This briefing seeks to enable housing associations to assess the significance
More informationDehns Guide to the Unitary Patent and Unified Patent Court
Dehns Guide to the Unitary Patent and Unified Patent Court Contents Introduction 1 Part I: The Unitary Patent 2 Part II: The Unified Patent Court 16 Part III: Implications for Brexit 32 Summary: How Dehns
More informationThe consequences of Brexit
The consequences of Brexit on Services and Establishment Different Scenarios for Exit and Future Cooperation Prof. Dr. Friedemann Kainer University of Mannheim 28 February 2017 IMCO workshop on Implications
More informationThe Conservative Manifesto 2017 Key points for the life sciences
The Conservative Manifesto 2017 Key points for the life sciences This document contains key excerpts for the life sciences from the Conservative manifesto. The full manifesto can be found here. Corporation
More informationBREXIT Chance und Herausforderung
BREXIT Chance und Herausforderung 13. September 2017 Dr. Christa Wirthumer-Hoche AGES Medizinmarktaufsicht, BASG Brexit With the trigger of Art 50 a 2 years transitional period started, Art 50 was triggered
More informationUK immigration briefing:
UK immigration briefing: Brexit and beyond webinar Thursday 7 December 2017 Key immigration concerns Current situation Preparing for change Proposals: current population Leaked proposals: future immigration
More informationEvidence submitted by Dr Federica Bicchi, Dr Nicola Chelotti, Professor Karen E Smith, Dr Stephen Woolcock
1 Submission of evidence for inquiry on the costs and benefits of EU membership for the UK s role in the world, for the House of Commons Foreign Affairs Committee Evidence submitted by Dr Federica Bicchi,
More informationIS 2016 THE FINAL STRETCH BEFORE THE ENTRY IN FORCE OF
IS 2016 THE FINAL STRETCH BEFORE THE ENTRY IN FORCE OF THE UNITARY PATENT AND THE UNIFIED PATENT COURT? By Christian TEXIER Partner, REGIMBEAU European & French Patent Attorney texier@regimbeau.eu And
More informationList of topics for papers
General information List of topics for papers The paper has to consist of 5 000-6 000 words (including footnotes). Please consider the formatting requirements. The deadline for submission will generally
More informationCollaboration among the regulatory authorities in the EU: a micro-agency s perspective. Alar Irs, Estonia
Collaboration among the regulatory authorities in the EU: a micro-agency s perspective Alar Irs, Estonia EU? 27 countries 23 languages 497 198 740 citizens GDP per capita: $28,213.00 EU? Member states
More informationBREXIT Seven alternatives to EU membership. Dr David Rees
BREXIT Seven alternatives to EU membership. Dr David Rees Referendum results UK budget contributions Difficult to get agreement on data (CAP?) See EU Commissionfigures UK immigration and salaries Option
More informationUNITARY PATENT PROTECTION (UPP) PACKAGE
UNITARY PATENT PROTECTION (UPP) PACKAGE LECCA & ASSOCIATES Ltd. August 1-2, 2014 Hong Kong, China SAR Objectives & Issues Creation of Unitary Patent (UP) Unitary Patent Court (UPC) A single harmonized
More informationThe US-China Business Council (USCBC)
COUNCIL Statement of Priorities in the US-China Commercial Relationship The US-China Business Council (USCBC) supports a strong, mutually beneficial commercial relationship between the United States and
More informationRESPONSE TO. Questionnaire. On the patent system in Europe INTRODUCTION
RESPONSE TO Questionnaire On the patent system in Europe INTRODUCTION PRIVACY STATEMENT I do consent to the publication of my personal data or data relating to my organisation with the publication of my
More informationAgreement on arrangements regarding citizens rights between Iceland, the Principality of Liechtenstein, the Kingdom of Norway and the United Kingdom
Agreement on arrangements regarding citizens rights between Iceland, the Principality of Liechtenstein, the Kingdom of Norway and the United Kingdom of Great Britain and Northern Ireland following the
More informationInternal EU27 preparatory discussions on the framework for the future relationship: "Mobility"
21 February 2018 TF50 (2018) 31 Commission to EU 27 Subject: Internal EU27 preparatory discussions on the framework for the future relationship: "Mobility" Origin: European Commission, Task Force for the
More informationDebevoise In Depth. Introduction
Debevoise In Depth No Divorce A New Cross-Channel Relationship? The Implications for Business of the UK s White Paper on Its Future Relationship with the European Union 18 July 2018 Introduction The UK
More informationEuropean Patent with Unitary Effect
European Patent with Unitary Effect and the Unified Patent Court May 2013 Dr Lee Chapman lchapman@jakemp.com www.jakemp.com Where are we? Regulations relating to the EPUE and translation arrangements were
More informationANNEX VI REFERRED TO IN ARTICLE 24 PROTECTION OF INTELLECTUAL PROPERTY
ANNEX VI REFERRED TO IN ARTICLE 24 PROTECTION OF INTELLECTUAL PROPERTY ANNEX VI REFERRED TO IN ARTICLE 24 PROTECTION OF INTELLECTUAL PROPERTY TITLE I GENERAL PROVISIONS Article 1 Definition of Intellectual
More informationBREXIT BRIEFING RULES OF ORIGIN
BREXIT BRIEFING RULES OF ORIGIN WHAT ARE RULES OF ORIGIN? Rules of Origin are the criteria used to determine the economic nationality of a product, as opposed to the geographic nationality of a product.
More informationGeneral Information Concerning. of IndusTRIal designs
General Information Concerning Patents The ReGIsTRaTIon For Inventions of IndusTRIal designs 1 2 CONTENTS INTRODUCTION 3 1. What is a patent? 4 2. How long does a patent last? 4 3. Why patent inventions?
More informationBrexit contingency planning for employers
Brexit Law your business, the EU and the way ahead Brexit contingency planning for employers October 2016 Overview The UK voted on Thursday 23 June to leave the European Union, marking the beginning of
More informationBrexit & Trade - Policy Recommendation to Government
Brexit & Trade - Policy Recommendation to Government Contents Introduction 1 EFTA 2 Candidate countries 4 Preferential Agreement 5 WTO (unilateral free trade) 5 Conclusion 7 Limitations 8 Bibliography
More informationSlide 13 What rights does a patent confer?
Slide 13 What rights does a patent confer? The term of the European patent shall be 20 years from the date of filing of the application (Article 63(1) EPC. However, nothing in Article 63(1) EPC shall limit
More informationPatent litigation. Block 3. Module UPC Law Essentials
Patent litigation. Block 3; Module UPC Law Patent litigation. Block 3. Module UPC Law Essentials Article 32(f) of the UPC Agreement ( UPCA ) states that subject to the transitional regime of Article 83
More informationCoordination group for Mutual recognition and Decentralised procedures (veterinary) RULES OF PROCEDURE
CMDv ROP-001-01 EMA/CMDv/37111/2011 London, 15 September 2011 Coordination group for Mutual recognition and Decentralised procedures (veterinary) RULES OF PROCEDURE Article 31 of Directive 2001/82/EC of
More informationBrinkhof. Defendant s Objection to the Application for Provisional Measures. Merva. Pentapharm
Brinkhof Unified Patent Court Local Division Milan [Address] Action number: [ ] Date oral hearing: 20 September 2016 Date submission: 6 September 2016 Defendant s Objection to the Application for Provisional
More informationArticle 1 General principles and objectives
NOTE: The EU reserves the right to make subsequent modifications to this text and to complement it at a later stage, by modifying, supplementing or withdrawing all, or any part, at any time. The relationship
More informationHow Are U.S. Multinationals Preparing for Brexit?
U.S. multinational companies are assessing the impact of Brexit on their European businesses, regional talent strategy and employee benefit plans. How Are U.S. Multinationals Preparing for Brexit? by Selima
More informationProposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL
EUROPEAN COMMISSION Strasbourg, 13.11.2018 COM(2018) 745 final 2018/0390 (COD) Proposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL amending Council Regulation (EC) No 539/2001 listing
More informationPossible models for the UK/EU relationship
Possible models for the UK/EU relationship This paper summarizes some potential alternative models for the UK s future relationship with the European Union, together with the key differences between the
More informationCanada Intellectual property enforcement
Sponsored by Statistical data supplied by Canada Intellectual property enforcement This article first appeared in IP Value 2004, Building and enforcing intellectual property value, An international guide
More informationTHE UEMS HOUSE - DOMUS MEDICA EUROPEA 22 MARCH 2017 BRUSSELS BREXIT TRADE HEALTH #BREXITHEALTH EVENT REPORT
THE UEMS HOUSE - DOMUS MEDICA EUROPEA 22 MARCH 2017 BRUSSELS BREXIT TRADE HEALTH #BREXITHEALTH EVENT REPORT Setting the scene The European Public Health Alliance (EPHA), in partnership with Manchester
More informationWIPO Sub-Regional Workshop on Patent Policy and its Legislative Implementation
WIPO Sub-Regional Workshop on Patent Policy and its Legislative Implementation Topic 12: Patent-related provisions in the framework of preferential trade agreements Marco M. ALEMAN Deputy Director, Patent
More informationAGREEMENT. On trade and economic cooperation between the Government of the Republic of Armenia and the Swiss Federal Council
AGREEMENT On trade and economic cooperation between the Government of the Republic of Armenia and the Swiss Federal Council The Government of the Republic of Armenia and the Swiss Federal Council hereinafter
More informationCBI MEMBERS AND THE UK-EU NEGOTIATION
CBI MEMBERS AND THE UK-EU NEGOTIATION POST-REFERENDUM INFORMATION PACK 21 JULY 2016 Introduction The UK has voted to leave the European Union. Now there are important questions that must be answered on
More informationA FAIR BREXIT FOR CONSUMERS
A FAIR BREXIT FOR CONSUMERS The People Roadmap Autumn 2017 #BREXIT CONTENTS Introduction 2 Recommendations 3 The importance of EU colleagues in retail 4 The share of EU nationals in the retail workforce
More informationThe Consolidate Utility Models Act 1)
Consolidate Act No. 220 of 26 February 2017 The Consolidate Utility Models Act 1) Publication of the Utility Models Act, cf. Consolidate Act No. 190 of 1 March 2016 including the amendments which follow
More informationMandate, objectives and rules of procedure
18 February 2014 EMA/INS/GMP/414260/2013 GMP/GDP inspectors working group (GMDP IWG) 1. General considerations In 1981 the European Commission established the Working Party on Control of Medicinal Products
More informationThe impact of Brexit on the pharmaceutical sector: Government Response to the Committee s Ninth Report
House of Commons Business, Energy and Industrial Strategy Committee The impact of Brexit on the pharmaceutical sector: Government Response to the Committee s Ninth Report Eleventh Special Report of Session
More informationBrexit: recent developments and some reflections. Professor Alex de Ruyter, Director, Centre for Brexit Studies
Brexit: recent developments and some reflections Professor Alex de Ruyter, Director, Centre for Brexit Studies Outline What is the Centre for Brexit Studies? Some Scenarios The way forward? What is the
More informationReasons to vote REMAIN
Why we should stay in the EU: A guide for Young Professionals Reasons to vote REMAIN YOUR EVERYDAY LIFE Brits paid less to use their phones on holidays in Europe last year thanks to EU laws We benefit
More informationFREE TRADE AGREEMENT BETWEEN THE REPUBLIC OF TURKEY AND THE REPUBLIC OF ALBANIA
FREE TRADE AGREEMENT BETWEEN THE REPUBLIC OF TURKEY AND THE REPUBLIC OF ALBANIA Free Trade Agreement Between the Republic of Turkey and the Republic of Albania PREAMBLE Desirous to develop and strengthen
More informationPHARMACEUTICAL COMMITTEE
EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market : management & legislation for consumer goods Pharmaceuticals : regulatory framework and market authorisations PHARM 466 PHARMACEUTICAL
More informationComparative Analysis of the U.S. Intellectual Property Proposal and Peruvian Law
!!! Dangers for Access to Medicines in the Trans-Pacific Partnership Agreement: Comparative Analysis of the U.S. Intellectual Property Proposal and Peruvian Law ! Issue US TPPA Proposal Andean Community
More informationCOMPULSORY LICENCE in Germany. Markus Rieck LL.M.
COMPULSORY LICENCE in Germany Markus Rieck LL.M. 1 1877 - GERMAN PATENT ACT Bundesarchiv, Bild 183-R68588 / P. Loescher & Petsch / CC-BY-SA 3.0 2 Public interest Dependent patent Plant breeders privilege*
More informationROMANIA Patent Law NO.64/1991 OFFICIAL GAZETTE OF ROMANIA, PART I, NO.613/19 AUGUST 2014
ROMANIA Patent Law NO.64/1991 OFFICIAL GAZETTE OF ROMANIA, PART I, NO.613/19 AUGUST 2014 TABLE OF CONTENTS CHAPTER I - GENERAL PROVISIONS Art. 1 Art. 2 Art. 3 Art. 4 Art. 5 CHAPTER II - PATENTABLE INVENTIONS
More informationRegulations to the Norwegian Patents Act (The Patent Regulations)
Regulations to the Norwegian Patents Act (The Patent Regulations) This is an unofficial translation of the regulations to the Norwegian Patents Act. Should there be any differences between this translation
More informationQUESTIONNAIRE ON THE PATENT SYSTEM IN EUROPE. 1.1 Do you agree that these are the basic features required of the patent system?
QUESTIONNAIRE ON THE PATENT SYSTEM IN EUROPE Section 1 1.1 Do you agree that these are the basic features required of the patent system? - We agree that clear substantive rules on patentability should
More informationAUTHORIZED ECONOMIC OPERATORS & MUTUAL RECOGNITION
AUTHORIZED ECONOMIC OPERATORS & MUTUAL RECOGNITION Rachel Dignam International Chamber of Commerce 05 December 2017 Istanbul, Turkey ICC: THE WORLD BUSINESS ORGANIZATION Business Associations sectoral
More informationMandate, objectives and rules of procedure
12 September 2013 Compliance and Inspections Good Clinical Practice Inspectors Working Group (GCP IWG) 1. General considerations In 1997, the Ad Hoc Meeting of GCP Inspection Services was established by
More informationOFFICIAL GAZETTE OF ROMANIA, PART I, NO.613/19 AUGUST 2014 REPUBLICATION PATENT LAW NO.64/1991 1
OFFICIAL GAZETTE OF ROMANIA, PART I, NO.613/19 AUGUST 2014 REPUBLICATION PATENT LAW NO.64/1991 1 CHAPTER I - GENERAL PROVISIONS Art. 1 - (1) The rights in inventions shall be recognized and protected on
More informationTOP 10 BREXIT MYTHS FOR FINANCIAL SERVICES FIRMS
TOP 10 BREXIT MYTHS FOR FINANCIAL SERVICES FIRMS This is a fraught time for in-house legal and compliance teams who are being expected to be conversant in all things Brexitrelated. We have compiled this
More informationRegulation relating to payments etc. to the Norwegian Industrial Property Office and the Board of Appeal for Industrial Property Rights
Regulation relating to payments etc. to the Norwegian Industrial Property Office and the Board of Appeal for Industrial Property Rights This is an unofficial translation of the Norwegian Designs Act. Should
More informationTrade-related intellectual property rights, trade in services and the fulfilment of children s rights - Botswana September 2004
Trade-related intellectual property rights, trade in services and the fulfilment of children s rights - Botswana September 2004 Introduction 1. Botswana has emerged as a model of access to medicines and
More informationUnitary Patent in Europe & Unified Patent Court (UPC)
Unitary Patent in Europe & Unified Patent Court (UPC) An overview and a comparison to the classical patent system in Europe 1 Today s situation: Obtaining patent protection in Europe Direct filing and
More informationOfficial Journal of the European Union L 334/7
12.12.2008 Official Journal of the European Union L 334/7 COMMISSION REGULATION (EC) No 1234/2008 of 24 November 2008 concerning the examination of variations to the terms of marketing authorisations for
More informationPatentable Subject Matter and Medical Use Claims in the Pharmaceutical Sector
Patentable Subject Matter and Medical Use Claims in the Pharmaceutical Sector 2012 LIDC Congress, Prague, 12 October 2012 Dr. Simon Holzer, Attorney-at-Law, Partner 3 October 2012 2 Introduction! Conflicting
More informationBrexit Transition Support for Local Cymdeithas Llywodraeth Leol Cymru Welsh Local Government Association
Cymdeithas Llywodraeth Leol Cymru Welsh Local Government Association Brexit Transition Support for Local Authorities Welsh NHS Confederation Event 22 nd March 2019 @WelshLGA www.wlga.wales Overview WLGA
More informationVIRK - Västsvenska Immaterialrättsklubben
VIRK - Västsvenska Immaterialrättsklubben Response to the Commission s Consultation on the patent system in Europe Issue description The Directorate General for Internal Market and Services is consulting
More informationGoing full circle: Bolar in Europe and the UPC
Going full circle: Bolar in Europe and the UPC ENGLAND, ROYLE AND DE COSTER : GOING FULL CIRCLE: BOLAR IN EUROPE AND THE UPC : VOL 14 ISSUE 2 BSLR 1 Article 10(6) of the Directive provides that the following
More informationSPC system simple, transparent and easy to apply? By Peter Damerell, Ayesha Raghib and William Hillson Powell Gilbert LLP
SPC system simple, transparent and easy to apply? By Peter Damerell, Ayesha Raghib and William Hillson Powell Gilbert LLP The strength and depth of our intellectual property expertise is second to none,
More informationLife after BREXIT: What are the UK s options outside the European Union? Swati Dhingra and Thomas Sampson
PAPERBREXIT01 Life after BREXIT: What are the UK s options outside the European Union? #CEPBREXIT Swati Dhingra and Thomas Sampson Disclaimer: The Centre for Economic Performance (CEP) is a politically
More informationHow will Brexit affect the public sector?
How will Brexit affect the public sector? Peter Village QC Timothy Lyons QC Justine Thornton QC Sian Davies Rose Grogan 21 st July 2016 How will Brexit affect local authorities powers and duties towards
More informationEMN Ad-Hoc Query on Ad hoc query on talent mobility
EMN Ad-Hoc Query on Ad hoc query on talent mobility Requested by ES EMN NCP on 11th October 2017 Economic Migration Responses from Austria, Belgium, Croatia, Czech Republic, Estonia, Finland, France, Germany,
More informationAccess to the Legal Services Market Post-Brexit
1 Access to the Legal Services Market Post-Brexit Summary The UK legal services market generated 3.3bn of our net export revenue in 2015. More importantly, our exporters confidence in doing business abroad
More informationBrexit: Unite demands protections for you
Brexit: Unite demands protections for you Road Transport Commercial Logistics and Retail Distribution Sector Road Transport - Commercial Road Transport - Commercial Brexit: Unite demands protections for
More informationBrexit. Alan V. Deardorff University of Michigan. For presentation at Adult Learning Institute April 11,
Brexit Alan V. Deardorff University of Michigan For presentation at Adult Learning Institute April 11, 2017 Brexit Defined: The exit of the United Kingdom from the European Union What that actually means
More information